Director, Regulatory Affairs - US Filing Lead Revolution MedicinesDirector, Regulatory Affairs - US Filing LeadRedwood City, California$211,000–$264,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Associate Director, Global Omnichannel Solutions Delivery Revolution MedicinesAssociate Director, Global Omnichannel Solutions DeliveryRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation.
Executive Director, Early Clinical Development Revolution MedicinesExecutive Director, Early Clinical DevelopmentRedwood City, California$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Portfolio Omnichannel (Lung HCP) Revolution MedicinesDirector, Portfolio Omnichannel (Lung HCP)Redwood City, California$211,000–$264,000 / yearThe Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Precision Medicine & Companion Diagnostics Revolution MedicinesAssociate Director, Precision Medicine & Companion DiagnosticsRedwood City, California$186,000–$233,000 / yearRevolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Revolution MedicinesAssociate Director, Clinical OperationsRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Senior Director, Talent Acquisition & Hrbp Maze TherapeuticsSenior Director, Talent Acquisition & HrbpSouth San Francisco, CA$270,000–$330,000 / yearOur clinical pipeline is anchored by two small molecule programs: MZE829, an APOL1 inhibitor for patients with APOL1‑mediated kidney disease, and MZE782, which targets genetic drivers of disease in phenylketonuria (PKU) and chronic kidney disease. We are seeking a Senior Director, Talent Acquisition & HRBP to lead hiring strategy and execution as the company advances its lead program into late‑stage development and prepares for continued organizational growth.
Senior Director, Clinical Data Management Revolution MedicinesSenior Director, Clinical Data ManagementRedwood City, California$244,000–$305,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials.
Senior Director, Global Patient Safety Operations Revolution Medicines IncSenior Director, Global Patient Safety OperationsRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.
Director Machine Learning, Drug Discovery Analytics Revolution Medicines IncDirector Machine Learning, Drug Discovery AnalyticsRedwood City, CA$273,000–$321,000 / yearThe successful candidate will play a key role in advancing a data-driven discovery strategy by designing predictive models, deploying innovative algorithms, and translating insights into actionable decisions that improve the speed and success of the discovery of medicines for patients with RAS-driven cancers. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, CMC Regulatory Revolution MedicinesAssociate Director, CMC RegulatoryRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As part of our expanding organization, we seek a strategic and hands-on Associate Director, CMC Regulatory who will be responsible for executing CMC regulatory strategies to support clinical development, marketing authorizations, and lifecycle management of RevMed’s pipeline compounds/products.
Director, Clinical Data Management Revolution MedicinesDirector, Clinical Data ManagementRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Senior Program Director (Commercial Regulatory Affairs, Fully Remote) Dawar ConsultingSenior Program Director (Commercial Regulatory Affairs, Fully Remote)South San Francisco, CaliforniaRemoteYou will lead Promotional Review Committees (PRCs), review and approve advertising and promotional materials, and partner closely with Marketing, Medical Affairs, Legal, and Compliance to ensure FDA‑compliant communications. Our client, a world leader in biotechnology and life sciences, is seeking a " Senior Program Director, Commercial Regulatory Affairs ".
Senior Director, Global Patient Safety Quality and Compliance Revolution Medicines IncSenior Director, Global Patient Safety Quality and ComplianceRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.
Director, Physician Researcher - Evidence Generation & Registries Verily Life Sciences LLCDirector, Physician Researcher - Evidence Generation & RegistriesSan Bruno, CAActing as a primary customer-facing expert, this leader will partner with health systems, academic investigators, payers, and pharmaceutical and other industry partners to design rigorous, operationally feasible studies and registries that demonstrate the clinical, operational, and population-level impact of products and programs. The ideal candidate combines deep clinical judgment, methodological fluency in observational and real-world evidence research, and the interpersonal skill to build trust with external partners while advancing Verily's scientific and business priorities.
Oversight Director, Clinical Operations Maze TherapeuticsOversight Director, Clinical OperationsSouth San Francisco, CA$232,000–$283,000 / yearCross-functional Collaboration Collaborate closely with Clinical Science, Regulatory Affairs, Data Science, Pharmacovigilance, Biometrics, Medical Monitoring, Clinical Supply, CMC, Tech Ops, Finance, and other cross-functional partners to influence asset strategy and drive successful program execution. Clinical Development & Portfolio Collaboration Provide strategic and operational direction across an assigned development asset spanning CKD and PKU clinical programs, ensuring alignment between clinical development strategy and operational execution from protocol development through study closeout and regulatory readiness.
Senior Director, Clinical Data Management (Clinical Data Systems and Ops Ex) Revolution MedicinesSenior Director, Clinical Data Management (Clinical Data Systems and Ops Ex)Redwood City, California$244,000–$305,000 / yearThe Senior Director of Clinical Data Management (CDS OpsEx) provides high-level leadership for Data Management and functions within clinical development including Information Operations, Data Products, and Clinical Data systems, focusing on strategic development, operational execution and excellence, and regulatory compliance to ensure data integrity for clinical trials. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Clinical Data Management Clinical Data Systems and Ops Ex Revolution Medicines IncSenior Director, Clinical Data Management Clinical Data Systems and Ops ExRedwood City, CA$244,000–$305,000 / yearThe Opportunity: The Senior Director of Clinical Data Management (CDS OpsEx) provides high-level leadership for Data Management and functions within clinical development including Information Operations, Data Products, and Clinical Data systems, focusing on strategic development, operational execution and excellence, and regulatory compliance to ensure data integrity for clinical trials. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Business Development (Healthcare Partnerships) 23andMe Research InstituteDirector, Business Development (Healthcare Partnerships)Palo Alto, CaliforniaYou will be responsible for identifying, pursuing, and closing deals with modern B2B2C partners (such as wellness hubs, longevity clinics, and specialized healthtech platforms), healthcare systems, and employers, to integrate our genomic insights into their clinical care stacks. Facilitate robust internal feasibility assessments of potential partnerships, using sound judgment and data to drive internal consensus on prospective deals.
Director HEOR Strategy Dermatology AbbVie IncDirector HEOR Strategy DermatologySouth San Francisco, CAThe Director, Health Economics & Outcomes Research (HEOR) leads the development & execution of projects for on-market and/or pipeline development assets, who is the brand/asset leader representing HEOR on cross functional asset/brand teams and in the pipeline commercialization teams. Applicable only to applicants applying to a position in any location with pay disclosure requirements under state or local law: The compensation range described below is the range of possible base pay compensation that the Company believes in good faith it will pay for this role at the time of this posting based on the job grade for this position.